Intracerebral haemorrhage: a need for more data and new research directions.

Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health (2013) 3.82

Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol (2010) 2.04

Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology (2011) 1.50

(-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways. Ann Clin Transl Neurol (2014) 1.04

Management of NCD in low- and middle-income countries. Glob Heart (2014) 0.97

History and mechanism for treatment of intracerebral hemorrhage with scalp acupuncture. Evid Based Complement Alternat Med (2012) 0.95

The CCL2-CCR2 system affects the progression and clearance of intracerebral hemorrhage. Glia (2012) 0.94

Intracerebral haemorrhage in a population-based stroke registry (LuSSt): incidence, aetiology, functional outcome and mortality. J Neurol (2013) 0.80

Microglial Polarization and Inflammatory Mediators After Intracerebral Hemorrhage. Mol Neurobiol (2016) 0.79

Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage. J Neuroinflammation (2016) 0.77

Translational intracerebral hemorrhage: a need for transparent descriptions of fresh tissue sampling and preclinical model quality. Transl Stroke Res (2015) 0.75

Inhibition of neuronal ferroptosis protects hemorrhagic brain. JCI Insight (2017) 0.75

Incidence and Mortality of Spontaneous Subarachnoid Hemorrhage in Martinique. PLoS One (2016) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21

Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med (2015) 12.06

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet (2012) 10.30

Stroke. Lancet (2008) 9.51

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 9.02

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25

1,026 experimental treatments in acute stroke. Ann Neurol (2006) 7.23

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32

Pooling of animal experimental data reveals influence of study design and publication bias. Stroke (2004) 4.37

Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust (2003) 4.24

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke (2008) 3.87

NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 3.70

Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke (2010) 3.43

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust (2004) 3.34

Good laboratory practice: preventing introduction of bias at the bench. Stroke (2008) 3.27

Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab (2005) 3.20

In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab (2013) 3.11

Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain (2007) 2.94

National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82

Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol (2002) 2.79

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack. N Engl J Med (2012) 2.39

NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke (2008) 2.39

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet (2011) 2.35

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31

Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke (2003) 2.25

Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol (2002) 2.25

Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust (2005) 2.20

The Stroke Riskometer(TM) App: validation of a data collection tool and stroke risk predictor. Int J Stroke (2014) 2.18

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Body mass index and survival in men and women aged 70 to 75. J Am Geriatr Soc (2010) 2.16

The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med J Aust (2002) 2.13

Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. Lancet Neurol (2006) 2.11

Warfarin-associated intracerebral hemorrhage: volume, anticoagulation intensity and location. J Neurol Sci (2013) 2.11

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol (2008) 2.07

Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology (2012) 2.06

National healthline responses to a stroke scenario: implications for early intervention. Stroke (2007) 2.06

Low molecular weight heparins and heparinoids. Med J Aust (2002) 2.06

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05

Emergency department workload increase: dependence on primary care? J Emerg Med (2009) 2.04

Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke (2011) 2.03

Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke (2004) 2.02

RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke (2011) 2.01

Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab (2009) 2.01

Are the national guidelines for health behaviour appropriate for older Australians? Evidence from the Men, Women and Ageing project. Australas J Ageing (2010) 2.01

Retinal microvasculature in acute lacunar stroke: a cross-sectional study. Lancet Neurol (2009) 2.01

Effective prophylaxis for deep venous thrombosis after stroke: both low-dose anticoagulation and stockings for most cases. Stroke (2004) 2.00

Does abnormal circadian blood pressure pattern really matter in patients with transient ischemic attack or minor stroke? Stroke (2014) 1.98

Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med (2010) 1.97

World Stroke Organization global stroke services guidelines and action plan. Int J Stroke (2014) 1.94

Distribution of airborne influenza virus and respiratory syncytial virus in an urgent care medical clinic. Clin Infect Dis (2010) 1.93

Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke (2007) 1.90

Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab (2010) 1.89

Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet (2012) 1.81

Insular cortical ischemia is independently associated with acute stress hyperglycemia. Stroke (2004) 1.81

Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke (2013) 1.79

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76

Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke (2007) 1.75

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev (2012) 1.72

Tissue plasminogen activator for ischaemic stroke: highly effective, reasonably safe and grossly underused. Med J Aust (2007) 1.71

Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology (2013) 1.69

Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery (2006) 1.68

Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab (2010) 1.68

Prevalence of sexual activity and associated factors in men aged 75 to 95 years: a cohort study. Ann Intern Med (2010) 1.67

150 minutes of vigorous physical activity per week predicts survival and successful ageing: a population-based 11-year longitudinal study of 12 201 older Australian men. Br J Sports Med (2013) 1.67

Incidence of stroke subtypes in the North East Melbourne Stroke Incidence Study (NEMESIS): differences between men and women. Neuroepidemiology (2008) 1.67

Acute stroke imaging research roadmap. Stroke (2008) 1.66

The physiological significance of the time-to-maximum (Tmax) parameter in perfusion MRI. Stroke (2010) 1.62

Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke (2010) 1.62

Evidence-based care and outcomes of acute stroke managed in hospital specialty units. Med J Aust (2003) 1.61

Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke (2003) 1.59

Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke (2004) 1.59

Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol (2009) 1.59

The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust (2008) 1.57

Alcohol use and mortality in older men and women. Addiction (2010) 1.55

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation (2014) 1.54

Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation. Cerebrovasc Dis (2011) 1.53